Tianjin Minxiang Biomedical Co.，Ltd.
Tianjin Minxiang Biomedical Co.，Ltd.
Main Products:1-Hydroxyadamantane, 1,3-Dimethyladamantane, 1-bromo-3,5-dimethyladamantane,
View moreAbout Us
Contact Supplier
Hot Products
+ more
1,3-Dimethyladamantane
Chemicals/Chemical Intermediates/Intermediate CompoundsNegotiable
Send Inquiry
1-bromo-3,5-dimethyladamantane
Chemicals/Chemical Intermediates/Methyl CompoundsNegotiable
Send Inquiry
3-trifluoro methyl-[1,2,4]triazole[4,3-a]piperazine hydrochloride
Chemicals/Heterocyclic Compounds/TriazolesNegotiable
Send Inquiry
(2S)-1-(Chloroacetyl)-2-pyrrolidinecarbonitrile
Chemicals/Chemical Intermediates/Intermediate CompoundsNegotiable
Send Inquiry
Boc-3-Hydroxy-1-adamantyl-D-glycine
Chemicals/Pharmaceutical Raw Materials/Amino Acids & DerivativesNegotiable
Send Inquiry
3-methylphenyl tricyclo[3.3.1.1~3,7~]decane-1-carboxylate
Chemicals/Hydrocarbons/AlkanesNegotiable
Send InquiryCompany Profile
+ more
Tianjin Minxiang Biomedical Co.，Ltd. (stock code: 834738) was founded in 2005 with registered capital of￥67.3 million. It is a high-tech enterprise that engages in researching, developing and manufacturing biological medicines, chemical raw medicines, preparations, intermediates, and new drugs.
The company has many R&D staffs in chemical synthesis, development of chemical technology, detection and quality analysis. Moreover, the company has hired some experts to offering guidance in the fields of information collection, R&D, and scientific research cooperation.
Insisting on technology innovation system of "combination of production, teaching and research", the company has cooperated with excellent experts and technicians of well-known universities for developing pharmaceutical raw materials and intermediates.
The company insists on strategic thinking of "taking processional scientific research and development as core, promoting comprehensive competitiveness of enterprise", and it encourages and supports the R&D of new products and technological innovation. Minxiang unremittingly increases investment in scientific research to promote R&D capability of the enterprise.
